Erratum: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial The results of the interim ...

Erratum: Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer ...

Erratum: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial ASCO Rapid Recommendation ...

Fig 2. Updated Recommendations. C, conditional; ECOG, Eastern Cooperative Oncology Group; L, low; LS, limited-stage; M, moderate; PS, performance status; S, strong ...

Sixty-two patients were enrolled in the study, with 53.2% female patients and a median age of 68 years. The most prevalent malignancy was thoracic (62.9%). The feasibility metric was met, with 45 ...

Improving Diagnosis and Care for Patients With Sarcoma: Do Real-World General Practitioners Data and Prospective Data Collections Have a Place Next to Clinical Trials? A thorough literature search was ...

The Journal of Clinical Oncology podcast, hosted by Dr. Shannon Westin, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.

A retrospective study was performed to analyze the results of clinical germline genetic testing (March 2020-January 2023) among a cohort of consecutive Emirati patients at risk for hereditary breast ...

Efficacy, Toxicity, and Cosmesis of Partial Breast Irradiation: Honing in on Dose and Patient Selection The following represents disclosure information provided by authors of this manuscript. All ...